• Genetic TherapyEnrolling

  Study of 4D-710 in Adults with Cystic Fibrosis , protocol number 4DMT 4D-710-C001 (Part 1 and 2)

  This study will test the safety and tolerability of 4D-710, an investigational gene therapy, in adults with CF who are not eligible for or are unable to tolerate CFTR modulator therapy.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    22

  • Length of Participation:

    1 years

• Restore CFTR ProteinEnrolling

  Study of VX-828 in combination with Tezacaftor and Deutivacaftor in healthy participants and in adults with cystic fibrosis. , protocol number Vertex VX23-828-001 Phase 1 Part E

  Part E of this study will look at the safety and tolerability of VX-828 in combination with Tezacaftor and Deutivacaftor in adults with CF. The drug combination is intended to help CFTR function closer to normal. 

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    12

  • Length of Participation:

    4 months

• Anti-InflammatoryEnrolling

  Study to evaluate BI 1291583 in adults with bronchiectasis , protocol number BI 1397-0014 (Airtivity)

  This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 100%

  • Number of Visits:

    9

  • Length of Participation:

    76 weeks

• Anti-InfectiveEnrolling

  Study to evaluate inhaled RSP-1502 in adults with cystic fibrosis and Pseudomonas aeruginosa , protocol number Respirion RESPIR-102

  This study will look at the safety of inhaled RSP-1502, a drug intended to treat infections in the lung. RSP-1502, which includes the antibiotic tobramycin, will be compared to tobramycin alone. The study will measure the drug's safety, how well it works, and how the body processes it. Four doses of RSP-1502 will be tested to find the best dose. 

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    4

  • Length of Participation:

    28 days

• ObservationalEnrolling

  REACH: An observational study for people with CF who do not take CFTR modulators , protocol number REACH-OB-23

  The REACH observational study will collect health information on people with CF 12 years and older who do not take CFTR modulators.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    12 months

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.